Publications by authors named "P Benvenuti"
Background: For the time being, tafamidis is the only approved treatment for wild-type transthyretin cardiac amyloidosis. However, benefits on all-cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age.
View Article and Find Full Text PDFIsatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.
Haematologica
November 2024
Article Synopsis
Background: Early identification of immunoglobulin light-chain amyloidosis (AL) is crucial due to its rapid progression. Monoclonal light-chain (M-LC) testing is the first step in the diagnostic workup for patients with suspected cardiac amyloidosis (CA). We aimed to determine whether the time interval between the first CA suspicion and M-LC testing can be related to AL amyloidosis survival outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Daratumumab-based treatments are considered the new standard therapy for newly diagnosed AL amyloidosis patients, supported by findings from the ANDROMEDA study.
- A prospective observational study involving 88 newly diagnosed patients explored daratumumab's efficacy and safety, revealing a low rate of serious side effects (16%) and a high overall hematologic response rate of 75%.
- The study found that daratumumab was effective in advanced cases, with similar rates of hematologic and organ responses between patients with more severe disease stages and those with less severe stages.
Key Points: Patients with AA amyloidosis and age ≥65 years, eGFR <45 ml/min per 1.73 m, and -terminal type-B natriuretic peptide >1000 ng/L and/or type-B natriuretic peptide >130 ng/L at diagnosis have poorer survival. Proteinuria >3.
View Article and Find Full Text PDF